Welcome to our dedicated page for COGNITION THERAPEUTICS SEC filings (Ticker: CGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognition Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing zervimesine for neurodegenerative diseases. Its Form 8-K reports cover financial results, Regulation FD presentations, clinical-development announcements, FDA meeting disclosures, and material agreements, including an at-the-market common-stock sales arrangement.
Proxy materials disclose annual meeting and stockholder voting matters, while registration and current-report disclosures identify the company’s Delaware corporate status, emerging growth company reporting status, and Nasdaq-listed common stock. The filings also provide formal records of capital-structure activity, governance processes, and risk areas associated with clinical research, regulatory review, grant funding, and the financing needs of a development-stage biotechnology company.
Cognition Therapeutics announced that the FDA provided written feedback aligning on key aspects of a pivotal Phase 3 trial of zervimesine (CT1812) for psychosis in dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis can be an approvable outcome to support a New Drug Application.
The planned registrational program is expected to begin in mid-2027 and will randomize people with DLB psychosis to receive 100 mg once-daily oral zervimesine or placebo for nine months, including patients on stable off-label antipsychotics. The company is working with the FDA to use the neuropsychiatric inventory (NPI) as a novel primary endpoint.
The study builds on Phase 2 SHIMMER data, where zervimesine showed improvements in psychosis symptoms versus placebo and, in a recent analysis, slowed progression of hallucinations and delusions by 89%. Cognition highlights a significant unmet need, noting that up to 80% of DLB patients experience psychosis and no drugs are currently approved for DLB.
Khattar Jack A. reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Jack A. Khattar received an equity award of 25,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock upon settlement. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholders’ meeting, contingent on his continued board service. Following this grant, Khattar directly holds 73,500 shares of common stock.
Monia Brett P reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Brett P. Monia received an award of 25,000 restricted stock units (RSUs). These RSUs represent a right to receive an equal number of common shares at no purchase price per share.
The RSUs vest in full on the earlier of June 17, 2027 or the date of the company’s next annual meeting of stockholders, as long as Monia continues to serve as a director through that date. Following this grant, Monia directly holds 73,500 shares of Cognition Therapeutics common stock.
Wallace Peggy reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics director Peggy Wallace received an equity grant tied to future stock. She was awarded 25,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest in full on the earlier of June 17, 2027, or the company’s next annual stockholder meeting, if she continues serving as a director. Following this grant, her directly held position reported in the filing is 111,461 shares. This is a compensation-related award rather than an open-market purchase.
Cognition Therapeutics director Ellen B. Richstone reported a grant of 25,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock upon settlement. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting, contingent on her continued board service. Following this equity award, she holds 83,500 shares of common stock directly. This Form 4 reflects a compensation-related acquisition rather than any open-market trading.
Fletcher Aaron G.L. reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Aaron G.L. Fletcher received an award of 25,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting, subject to his continued board service.
The filing shows 81,229 common shares held directly after the award, and additional indirect holdings through multiple Bios-affiliated investment funds. Under existing agreements, Fletcher holds certain equity awards as a nominee for BP Directors, LP, and various Bios and Cavu entities may be deemed indirect beneficial owners, while all reporting persons disclaim beneficial ownership beyond any pecuniary interest.
Cognition Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2026, conducted virtually. Stockholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting and until their successors are elected or appointed.
Fletcher received 15,093,537 votes for and 680,677 withheld, while Ricciardi received 15,094,238 votes for and 679,976 withheld, with 34,035,661 broker non-votes for each. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year, with 49,039,407 votes for, 126,951 against, and 643,517 abstentions.
Cognition Therapeutics, Inc. furnished an investor presentation under Regulation FD, outlining its strategy as a clinical-stage CNS drug developer focused on zervimesine (CT1812). The company highlights Dementia with Lewy bodies (DLB) psychosis as its lead indication, with a Phase 3 registrational trial in development following the SHIMMER Phase 2 study.
As of March 31, 2026, Cognition reports approximately $31 million in cash, equivalents and restricted cash, $25 million in obligated NIA grant funds, and a cash runway into Q2 2027 based on its current operating plan. The presentation notes more than $170 million in cumulative NIH/NIA grant support and a workforce of about 14 employees.
The deck describes SHIMMER Phase 2 results in DLB, including slowing of neuropsychiatric decline on the NPI-12 measure versus placebo, and plans for a 9‑month registrational study in DLB psychosis overseen by the FDA’s Division of Psychiatry. It also details Alzheimer’s programs, including the completed SHINE Phase 2 trial and the ongoing 545‑patient START trial in MCI through mild Alzheimer’s disease funded by an $81 million NIA grant.
Cognition Therapeutics reported that it has completed a planned meeting with the U.S. Food and Drug Administration to discuss zervimesine (CT1812) for dementia with Lewy bodies patients with psychosis. The discussion reviewed Phase 2 SHIMMER results and potential design and endpoints for a registrational trial.
The company said the interaction was productive and believes there is a path forward to develop zervimesine for DLB psychosis, with formal FDA meeting minutes expected in June. Zervimesine is an investigational once-daily oral therapy that has shown promise in Phase 2 studies in DLB and mild-to-moderate Alzheimer’s disease.
Cognition noted it has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its neurodegenerative disease research and clinical programs.
Cognition Therapeutics’ Q1 2026 report shows a smaller loss while it continues advancing its neurology pipeline. Net loss narrowed to $4,570 thousand, or $0.05 per share, compared with $8,480 thousand, or $0.14 per share, a year earlier. Operating expenses fell as research and development dropped to $6,120 thousand from $10,786 thousand, reflecting lower clinical program and personnel costs.
The company generated $3,979 thousand of grant income, mainly from U.S. National Institute on Aging awards funding its Alzheimer’s and dementia with Lewy bodies studies. Cash, cash equivalents and restricted cash totaled $31.2 million, and management believes this, together with existing NIA grant support, can fund operations through the second quarter of 2027. Lead candidate zervimesine (CT1812) remains in multiple Phase 2 programs for Alzheimer’s disease and DLB, with large NIA grants and a 2025 shelf registration and at-the-market program providing additional financing flexibility.